Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online: 33

 Table of Contents  
Year : 2013  |  Volume : 10  |  Issue : 4  |  Page : 14-17

Non invasive and percutaneous ablation of nontoxic solid nodules

Department of Endocrinology, Army Hospital R and R, Delhi, India

Date of Web Publication2-Feb-2013

Correspondence Address:
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0973-0354.106810

Rights and Permissions

How to cite this article:
Kotwal N, Pandit A. Non invasive and percutaneous ablation of nontoxic solid nodules. Thyroid Res Pract 2013;10, Suppl S1:14-7

How to cite this URL:
Kotwal N, Pandit A. Non invasive and percutaneous ablation of nontoxic solid nodules. Thyroid Res Pract [serial online] 2013 [cited 2022 Dec 5];10, Suppl S1:14-7. Available from: https://www.thetrp.net/text.asp?2013/10/4/14/106810

  Introduction Top

Thyroid nodules (TN) are very commonly seen in general population with a prevalence of about 4% by palpation and up to 10-41% with the use of ultrasound. [1] Majority of the TNs are benign, [2] and few of the benign nodules warrant treatment for pressure symptoms and for cosmetic reasons. Surgery and radioiodine therapy have been the mainstay of therapy in the compressive TNs, but surgical complications have been reported in around 7-10% of cases. [3] Also, the risk of thyroid surgery is definitely more in the elderly population and it is refused by many. Medical therapy using levothyroxine in non-functioning TNs achieves very little goitre shrinkage and also the risk of suppressing thyroid stimulating hormone (TSH) remains. [4] Non-surgical or minimally invasive methods of treating TN are being investigated. Ethanol ablation (EA), percutaneous radiofrequency ablation (RFA), and laser ablation have been used. Recently, high intensity focussed ultrasound (HIFU) and microwave ablation as thermal ablation have been tried. In this review, we will be discussing the non-invasive modes of treating solid TNs.

  Radiofrequency Ablation Top

RFA was first tried in the treatment of liver cancer [5] and was introduced in the treatment of TNs in 2006. Kanauchi et al. [6] demonstrated in pigs that percutaneous RFA induced necrosis of thyroid tissue. Mallery et al. [7] successfully used RFA for treating hyperthyroidism in cats, although the effect was transient.

Principle of RFA

RFA uses the heat generated from high frequency alternating electric current between 200 and 1200 KHz. The radiofrequency waves pass through electrodes and agitate the tissue ions around the electrodes. They generate frictional heat and increase the temperature in the tissue, resulting in the destruction of the tissue. Also, the conduction heat from the ablated area can damage the tissue away from the electrode in a slower fashion. Frictional heat and conduction heat are the two basic principles of RFA.


The moving shot technique has been recommended to optimise the efficacy and minimize the complications. The TNs are divided into multiple conceptual units and the nodule is ablated unit by unit. The electrode is placed in the deepest portion of the nodule and then moved backward in the superficial direction. The extent of the ablated area is determined by the echogenic changes. It is performed under ultrasonographic guidance after local anesthesia, usually using the trans isthmic area. This approach has several advantages like clear view of the electrode in the transverse ultrasound view and minimal heat exposure to the danger area that is near the recurrent laryngeal nerve and/or the esophagus. [8]


Many studies have demonstrated the safety and the efficacy of RFA. [3],[9],[10],[11],[[12] A recently published study [3] demonstrated the efficacy and safety of RFA in both toxic and non-toxic solid nodule as compared to no treatment at all. They demonstrated a reduction in TN volume of up to 94% at the end of 9 months and also reduction in the pressure symptoms. [3]

These results were similar to that in a randomized prospective study by Baek et al. [13] Another follow-up study of 126 benign TNs in 111 patients over 4 years reported a decrease in the TN volume of up to 93.5% at the end of 4 years. [14] A large series study of 236 patients demonstrated a volume reduction of up to 84% in 6 months. Also, 91% of nodules were reduced by 50%, indicating therapeutic success. [10] The greatest volume reduction was observed in the first month post RFA with further declining volume with time. [10],[13] It has been demonstrated that a single session of RFA is sufficient to decrease the thyroid volume and ameliorate the cosmetic and the pressure symptoms. [13] A recurrence rate of 5.6% was found over a follow-up of 4 years, although none of the nodules grew to a size larger than its initial volume. [14] Complete ablation of periphery is important to prevent the marginal tumor regrowth, which may be required in larger nodules, and the moving shot technique has been proposed as a suitable method. [9],[13],[15] RFA is also effective in treatment of benign predominantly cystic TNs with a residual solid component in patients whose clinical problems were incompletely resolved after EA. [16] RFA is effective in solid nodules in patients with incompletely resolved clinical problems after EA, indicating that RFA is effective for both solid and cystic component. [17] Recently, Korean society of thyroid radiology published a consensus statement regarding the use of thermal ablation laser and radiofrequency in TNs. [18]


In a retrospective study conducted on 1459 patients who underwent RFA, the complication rate was 3.3% and major complication rate was 1.4%. Major complications were voice change, brachial plexus injury, tumor rupture, and permanent hypothyroidism. Minor complications were hematoma, skin burn, and vomiting. [19] Pain was the commonest complaint reported post procedure and around 5.5% patients required analgesics for the same. [10] Kim et al. reported that recurrent laryngeal nerve injury after RFA was 3.3%. [11] Knowledge of the danger triangle and the variations in the vagus nerve can help prevent the recurrent laryngeal injury. Hematomas can be prevented by local compression. Nodule rupture usually occurs due to hematoma in the TN and can be conservatively managed with antibiotics and/or analgesics.

  Laser Ablation Top

Laser ablation concept was initially described in 1983 by Bown. [20]


Light is delivered interstitially by implanting a laser fibre directly into the tissues. Interstitial laser ablation is a thermal technique aiming at conversion by tissue into heat of light produced by sources such as neodimium-yttrium aluminium garnet (ND-YAG) with a wavelength of 1064 nm or continuous (820 nm) diode laser. The delivered photons cause increase in the temperature, followed by denaturation of the irradiated cells. Laser ablation induces a zone of coagulative necrosis with well-defined margins when temperature exceeds 60°C (threshold for protein denaturation) with irreversible tissue destruction and with no viable tissue remaining inside. [21]


Based on experimental studies in animals, a first feasibility was conducted in 2000 by Pacella et al. [22] Many uncontrolled trials have demonstrated the efficacy of laser ablation in TNs. [23],[24],[25] A large series of 122 patients were followed-up for a period of 3 years. The thyroid volume decreased by 50% in a wide-size range of nodules. [26] In another prospective randomised study by Dossing et al. showed that a single treatment with ultrasound-guided LA reduced the thyroid volume by almost 50%. The incremental effect of additional laser was minimal. [27] A randomized controlled trial showed that nodules decreased significantly by 22% after 2 weeks and by 44% after 30 weeks. [28] In another randomized controlled trial demonstrated a volume reduction >50% was found in 33.3% of cases. [29] A study in 2009 demonstrated a dose-response relationship of laser ablation. [30] Also, a recent study demonstrated that only high energy (>400-500 J/ml of nodular tissue to be treated) of laser energy is needed for it to be effective over time. [31] Also, the concern regarding the histopathological changes seen in TN after laser ablation was studied in a series of 22 patients followed-up for 18 months. It was demonstrated that LA treatment is safe and can be followed-up with fine needle aspiration cytology. [32] Similar results were found by Cakir et al. [33] In a comparative study between laser ablation and RFA found that laser ablation as well as RFA are suitable for singular TNs and induces reproducible clinically relevant lesions in an appropriate application time. The maximum inducible lesion volumes by laser ablation are significantly larger than by RFA with the devices used herein. [34]


Complications associated with LA are rare and usually temporary. Transient dysphonia, pain, fever, mild burns, and skin infections have been reported. [21]

  Ethanol Ablation Top

EA was first used for a successful renal cyst ablation in 1981 [35] and, subsequently, was demonstrated to be effective in treatment of hepatic cysts, [36] malignant liver lesions, [37] and primary hyperparathyroidism. [38] Ethanol causes thyroid tissue destruction by complex mechanisms like coagulative necrosis, vascular thrombosis, and hemorrhagic infarction. [39] Livraghi et al. first demonstrated the use of EA in hyperfunctioning TNs in 1990. [40] Since then, EA has been established as the first-line of treatment for benign cystic TNs. However, the data regarding use of EA in solid nodules is variable and depends on the nodule size, volume of ethanol instilled, and nodule toxicity. [41],[42],[43] A recently published study, however, demonstrated a success rate of 60% in solid nodules. Nodular vascularity and the degree of intranodular echo staining after EA on color Doppler sonography were useful in predicting the success rate for benign predominantly solid nodules. [44] Limitations include repeated use of EA, painful despite local anesthesia, fever, periglandular fibrosis, or dysphonia. A sudden increase in the intranodal pressure can cause leakage of ethanol extranodally. [45]

  Newer Modalities Top

Microwave thermal ablation

Microwave ablation uses electromagnetic energy typically operated at 915 MHz or 2.45 GHz, causing tissue destruction using thermal energy. When electromagnetic energy is applied over the tissue, the energy is used to force molecules to continuously realign with the applied field. This rotation of molecules represents an increase in kinetic energy and, hence, an elevation in local tissue temperatures. [46] Microwave ablation has been used for the treatment of hepatic malignancies, [47] lung malignancies, [48] and lung cancer. [49] Its use in TN ablation has been demonstrated recently. In a recently published study in January 2013, a total of 477 benign TNs in 222 patients underwent microwave ablation. A volume-reduction ratio >50% was observed in 82.3% of index nodules and 30.7% of index nodules disappeared 6 month after the ablation. They did not report any major complications. [50] Another study demonstrated a volume-reduction ratio of up to 45%. One case report of laryngeal nerve palsy and tracheal cartilage necrosis after microwave ablation has been reported as well. [51]

  High Intensity Focussed Ultrasound Top

HIFU relies on the same principle as ultrasound. When focussed ultrasound waves passes through a tissue, it causes local rise of temperature, causing tissue necrosis. [52] In 1950, Fry et al. demonstrated the use of HIFU by producing lesions in the brains of cats and monkeys. [53],[54] It has been used in the treatment of benign prostratic hyperplasia, liver cancer, and prostrate cancer. [52] Esnault et al. have conducted the first human feasibility study on 25 patients. Among the 25 patients, 16 showed a significant response on ultrasound. They did not report any complications. [55] Although it appears as an exciting prospect, much research is needed yet.

  Conclusion Top

The non-invasive and percutaneous methods like laser ablation and RFA are good alternatives to benign solid TNs, especially in patients refusing surgery and those with cosmetic problems. EA, though effective in cystic nodules, its use in solid nodules is limited with the conflicting data available. The newer modalities are all an interesting prospect in our never ending search for an ideal alternative to surgery, which is minimaly invasive, although further studies need to determine its efficacy in the treatment of TNs.

  References Top

1.Weiss RE, Lado-Abeal J. Thyroid nodules: Diagnosis and therapy. Curr Opin Oncol 2002;14:46-52.  Back to cited text no. 1
2.Tan GH, Gharib H. Thyroid incidentalomas: Management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226-31.  Back to cited text no. 2
3.Faggiano A, Ramundo V, Assanti AP, Fonderico F, Macchia PE, Misso C, et al. Thyroid nodules treated with percutaneous radiofrequency thermal ablation: A comparative study. J Clin Endocrinol Metab 2012;97:4439-45.  Back to cited text no. 3
4.Gharib H, Papini E, Valcavi R, Baskin HJ, Crescenzi A, Dottorini ME, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2006;12:63-102.  Back to cited text no. 4
5.Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, et al. Percutaneous radiofrequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am 1995;1:73-81.  Back to cited text no. 5
6.Kanauchi H, Mimura Y, Kaminishi M. Percutaneous radio-frequency ablation of the thyroid guided by ultrasonography. Eur J Surg 2001;167:305-7.  Back to cited text no. 6
7.Mallery KF, Pollard RE, Nelson RW, Hornof WJ, Feldman EC. Percutaneous ultrasound-guided radiofrequency heat ablation for treatment of hyperthyroidism in cats. J Am Vet Med Assoc 2003;223:1602-7.  Back to cited text no. 7
8.Shin JH, Baek JH, Ha EJ, Lee JH. Radiofrequency ablation of thyroid nodules: Basic principles and clinical application. Int J Endocrinol 2012;2012:919650.  Back to cited text no. 8
9.Baek JH, Moon WJ, Kim YS, Lee JH, Lee D. Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules. World J Surg 2009;33:1971-7.  Back to cited text no. 9
10.Jeong WK, Baek JH, Rhim H, Kim YS, Kwak MS, Jeong HJ, et al. Radiofrequency ablation of benign thyroid nodules: Safety and imaging follow-up in 236 patients. Eur Radiol 2008;18:1244-50.  Back to cited text no. 10
11.Kim YS, Rhim H, Tae K, Park DW, Kim ST. Radiofrequency ablation of benign cold thyroid nodules: Initial clinical experience. Thyroid 2006;16:361-7.  Back to cited text no. 11
12.Spiezia S, Garberoglio R, Milone F, Ramundo V, Caiazzo C, Assanti AP, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid 2009;19:219-25.  Back to cited text no. 12
13.Baek JH, Kim YS, Lee D, Huh JY, Lee JH. Benign predominantly solid thyroid nodules: Prospective study of efficacy of sonographically guided radiofrequency ablation versus control condition. AJR Am J Roentgenol 2010;194:1137-42.  Back to cited text no. 13
14.Lim HK, Lee JH, Ha EJ, Sung JY, Kim JK, Baek JH. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. Eur Radiol 2012.  Back to cited text no. 14
15.Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG. Thermal ablation for benign thyroid nodules: Radiofrequency and laser. Korean J Radiol 2011;12:525-40.  Back to cited text no. 15
16.Jang SW, Baek JH, Kim JK, Sung JY, Choi H, Lim HK, et al. How to manage the patients with unsatisfactory results after ethanol ablation for thyroid nodules: Role of radiofrequency ablation. Eur J Radiol 2012;81:905-10.  Back to cited text no. 16
17.Lee JH, Kim YS, Lee D, Choi H, Yoo H, Baek JH. Radiofrequency ablation (RFA) of benign thyroid nodules in patients with incompletely resolved clinical problems after ethanol ablation (EA). World J Surg 2010;34:1488-93.  Back to cited text no. 17
18.Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, et al. Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: Consensus statement and recommendations. Korean J Radiol 2012;13:117-25.  Back to cited text no. 18
19.Baek JH, Lee JH, Sung JY, Bae JI, Kim KT, Sim J, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: A multicenter study. Radiology 2012;262:335-42.  Back to cited text no. 19
20.Bown SG. Phototherapy in tumors. World J Surg 1983;7:700-9.  Back to cited text no. 20
21.Papini E, Bizzarri G, Pacella CM. Percutaneous laser ablation of benign and malignant thyroid nodules. Curr Opin Endocrinol Diabetes Obes 2008;15:434-9.  Back to cited text no. 21
22.Pacella CM, Bizzarri G, Guglielmi R, Anelli V, Bianchini A, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology 2000;217:673-7.  Back to cited text no. 22
23.Døssing H, Bennedbaek FN, Karstrup S, Hegedüs L. Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation--initial experience. Radiology 2002;225:53-7.  Back to cited text no. 23
24.Pacella CM, Bizzarri G, Spiezia S, Bianchini A, Guglielmi R, Crescenzi A, et al. Thyroid tissue: US-guided percutaneous laser thermal ablation. Radiology 2004;232:272-80.  Back to cited text no. 24
25.Papini E, Guglielmi R, Bizzarri G, Pacella CM. Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules. Endocr Pract 2004;10:276-83.  Back to cited text no. 25
26.Valcavi R, Riganti F, Bertani A, Formisano D, Pacella CM. Percutaneous laser ablation of cold benign thyroid nodules: A 3-year follow-up study in 122 patients. Thyroid 2010;20:1253-61.  Back to cited text no. 26
27.Døssing H, Bennedbaek FN, Hegedüs L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: One versus three treatments. Thyroid 2006;16:763-8.  Back to cited text no. 27
28.Gambelunghe G, Fatone C, Ranchelli A, Fanelli C, Lucidi P, Cavaliere A, et al. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: One versus three treatments. Thyroid 2006;16:763-8.  Back to cited text no. 28
29.Papini E, Guglielmi R, Bizzarri G, Graziano F, Bianchini A, Brufani C, et al. Treatment of benign cold thyroid nodules: A randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid 2007;17:229-35.  Back to cited text no. 29
30.Ritz JP, Lehmann KS, Zurbuchen U, Knappe V, Schumann T, Buhr HJ, et al. Ex vivo and in vivo evaluation of laser-induced thermotherapy for nodular thyroid disease. Lasers Surg Med 2009;41:479-86.  Back to cited text no. 30
31.Gambelunghe G, Fede R, Bini V, Monacelli M, Avenia N, D'Ajello M, et al. Ultrasound-guided interstitial laser ablation for thyroid nodules is effective only at high total amounts of energy: Results from a three-year pilot study. Surg Innov 2012.   Back to cited text no. 31
32.Piana S, Riganti F, Froio E, Andrioli M, Pacella CM, Valcavi R. Pathological findings of thyroid nodules after percutaneous laser ablation: A series of 22 cases with cyto-histological correlation. Endocr Pathol 2012;23:94-100.  Back to cited text no. 32
33.Cakir B, Topaloglu O, Gul K, Agac T, Aydin C, Dirikoc A, et al. Effects of percutaneous laser ablation treatment in benign solitary thyroid nodules on nodule volume, thyroglobulin and anti-thyroglobulin levels, and cytopathology of nodule in 1 yr follow-up. J Endocrinol Invest 2006;29:876-84.  Back to cited text no. 33
34.Ritz JP, Lehmann KS, Schumann T, Knappe V, Zurbuchen U, Buhr HJ, et al. Effectiveness of various thermal ablation techniques for the treatment of nodular thyroid disease-comparison of laser-induced thermotherapy and bipolar radiofrequency ablation. Lasers Med Sci 2011;26:545-52.  Back to cited text no. 34
35.Bean WJ. Renal cysts: Treatment with alcohol. Radiology 1981;138:329-31.  Back to cited text no. 35
36.Bean WJ, Rodan BA. Hepatic cysts: Treatment with alcohol. AJR Am J Roentgenol 1985;144:237-41.  Back to cited text no. 36
37.Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.  Back to cited text no. 37
38.Harman CR, Grant CS, Hay ID, Hurley DL, van Heerden JA, Thompson GB, et al. Indications, technique, and efficacy of alcohol injection of enlarged parathyroid glands in patients with primary hyperparathyroidism. Surgery 1998;124:1011-9.  Back to cited text no. 38
39.Crescenzi A, Papini E, Pacella CM, Rinaldi R, Panunzi C, Petrucci L, et al. Morphological changes in a hyperfunctioning thyroid adenoma after percutaneous ethanol injection: Histological, enzymatic and sub-microscopical alterations. J Endocrinol Invest 1996;19:371-6.  Back to cited text no. 39
40.Livraghi T, Paracchi A, Ferrari C, Bergonzi M, Garavaglia G, Raineri P, et al. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: Preliminary results. Radiology 1990;175:827-9.  Back to cited text no. 40
41.Goletti O, Monzani F, Lenziardi M, Lippolis PV, De Negri F, Caraccio N, et al. Cold thyroid nodules: A new application of percutaneous ethanol injection treatment. J Clin Ultrasound 1994;22:175-8.  Back to cited text no. 41
42.Bennedbak FN, Hegedus L. Alcohol sclerotherapy for benign solitary solid cold thyroid nodules. Lancet 1995;346:1227.  Back to cited text no. 42
43.Zingrillo M, Collura D, Ghiggi MR, Nirchio V, Trischitta V. Treatment of large cold benign thyroid nodules not eligible for surgery with percutaneous ethanol injection. J Clin Endocrinol Metab 1998;83:3905-7.  Back to cited text no. 43
44.Kim DW, Rho MH, Park HJ, Kwag HJ. Ultrasonography-guided ethanol ablation of predominantly solid thyroid nodules: A preliminary study for factors that predict the outcome. Br J Radiol 2012;85:930-6.  Back to cited text no. 44
45.Guglielmi R, Pacella CM, Bianchini A, Bizzarri G, Rinaldi R, Graziano FM, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid 2004;14:125-31.  Back to cited text no. 45
46.Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011;258:351-69.  Back to cited text no. 46
47.Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: Treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 2009;251:933-40.  Back to cited text no. 47
48.Liang P, Wang Y, Zhang D, Yu X, Gao Y, Ni X. Ultrasound guided percutaneous microwave ablation for small renal cancer: Initial experience. J Urol 2008;180:844-8.  Back to cited text no. 48
49.Wolf FJ, Grand DJ, Machan JT, Dipetrillo TA, Mayo-Smith WW, Dupuy DE. Microwave ablation of lung malignancies: Effectiveness, CT findings, and safety in 50 patients. Radiology 2008;247:871-9.  Back to cited text no. 49
50.Yue W, Wang S, Wang B, Xu Q, Yu S, Yonglin Z, et al. Ultrasound guided percutaneous microwave ablation of benign thyroid nodules: Safety and imaging follow-up in 222 patients. Eur J Radiol 2013;82:e11-6.  Back to cited text no. 50
51.Feng B, Liang P, Cheng Z, Yu X, Yu J, Han Z, et al. Ultrasound-guided percutaneous microwave ablation of benign thyroid nodules: Experimental and clinical studies. Eur J Endocrinol 2012;166:1031-7.  Back to cited text no. 51
52.Kennedy JE, Ter Haar GR, Cranston D. High intensity focused ultrasound: Surgery of the future? Br J Radiol 2003;76:590-9.  Back to cited text no. 52
53.Fry WJ, Mosberg WH Jr, Barnard JW, Fry FJ. Production of focal destructive lesions in the central nervous system with ultrasound. J Neurosurg 1954;11:471-8.  Back to cited text no. 53
54.Fry WJ, Barnard JW, Fry EJ, Krumins RF, Brennan JF. Ultrasonic lesions in the mammalian central nervous system. Science 1955;122:517-8.  Back to cited text no. 54
55.Esnault O, Franc B, Ménégaux F, Rouxel A, De Kerviler E, Bourrier P, et al. High-intensity focused ultrasound ablation of thyroid nodules: First human feasibility study. Thyroid 2011;21:965-73.  Back to cited text no. 55


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Radiofrequency A...
Laser Ablation
Ethanol Ablation
Newer Modalities
High Intensity F...

 Article Access Statistics
    PDF Downloaded292    
    Comments [Add]    

Recommend this journal